Burkitt Lymphoma Clinical Trial
Official title:
Phase II Study of Intensive Chemotherapy and Rituximab in Burkitt Lymphoma
The purpose of this study is to learn more about how well a chemotherapy regime including rituximab works in treating patients with Burkitt or atypical Burkitt lymphoma.
- Patients will be placed into one of two groups, "low risk" and "high risk". "Low risk"
disease is defined as one area of disease measuring less than 10cm and a normal blood
test called LDH (lactate hydrogenase). Patients not fitting the "low risk" criteria are
considered "high risk".
- If the patient has "low risk" disease their treatment cycle consist of three cycles of
A.
- If the patient has "high risk" disease they will receive Cycle A followed by cycle B
which will then repeat.
- Cycle A consists of the drugs: rituximab, cyclophosphamide, oncovin, doxorubicin and
methotrexate (R-CODOX-M). The treatment cycle is approximately 14 days. A spinal tap is
performed on day 1 and day 3 of the cycle and the patient will be hospitalized until
between day 11 and day 13. After the patient's blood counts return to normal(usually
around day 21),the next round of treatment will occur.
- Cycle B consists of the drugs: rituximab, ifosfamide, VP-16 and ara-c (IVAC). The
treatment cycle is approximately 5 days. A spinal tap is performed on day 4 and once
blood counts return to normal the patient will start cycle A again.
- After the patient has finished the treatments, they will be re-evaluated with CT scans
and PET scans to determine whether or not they are in remission. Every three months for
two years, blood tests and CT and PET scans will be performed. Follow up after that
will be every 6 months for two years.
;
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01943682 -
Safety Study of CPX-351 in Children With Relapsed Leukemia or Lymphoma
|
Phase 1 | |
| Completed |
NCT01093586 -
Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies
|
Phase 2 | |
| Recruiting |
NCT05020392 -
Autologous Cells Derived Anti-CD19 CAR-Engineered T Cells With Concurrent BTK Inhibitor for B Cell Lymphoma
|
Phase 3 | |
| Recruiting |
NCT04545762 -
Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma
|
Phase 1 | |
| Terminated |
NCT03864419 -
Rituximab Hyaluronidase in Combination With Chemotherapy in Treating Aggressive B-cell Lymphoma in Uganda
|
Phase 1 | |
| Terminated |
NCT02700022 -
A Phase I Study of Alisertib + R-EPOCH for Treatment of Myc-Positive Aggressive B-cell Lymphomas
|
Phase 1 | |
| Completed |
NCT00849147 -
Bone Marrow Transplant From Partially Matched Donors and Nonmyeloablative Conditioning for Blood Cancers (BMT CTN 0603)
|
Phase 2 | |
| Completed |
NCT00822432 -
Coproporphyrine Isomers and Methotrexate Elimination
|
N/A | |
| Recruiting |
NCT00180882 -
LMBA02 Protocol for Patients With a Burkitt Lymphoma
|
Phase 3 | |
| Recruiting |
NCT06060782 -
Thiotepa, Cyclophosphamide, Clarithromycin and Cytarabine
|
Phase 1 | |
| Active, not recruiting |
NCT02996773 -
Haploidentical BMT With Post-Transplant Cyclophosphamide and Bendamustine
|
Phase 1 | |
| Recruiting |
NCT05565417 -
Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT03298828 -
CD19 CAR and PD-1 Knockout Engineered T Cells for CD19 Positive Malignant B-cell Derived Leukemia and Lymphoma
|
Phase 1 | |
| Completed |
NCT01290120 -
Chemotherapy Plus Rituximab Combination for Adult Lymphoblastic Leukemia (B-ALL) and Burkitt's Non-Hodgkin Lymphoma
|
Phase 2 | |
| Active, not recruiting |
NCT00719888 -
Umbilical Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With Hematologic Disease
|
Phase 2 | |
| Recruiting |
NCT06131801 -
Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
|
||
| Recruiting |
NCT04425421 -
Recommendations for the Treatment of Children With Burkitt's Lymphoma
|
||
| Active, not recruiting |
NCT00001337 -
Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Previously Untreated Aggressive Non-Hodgkin's Lymphoma
|
Phase 2 | |
| Recruiting |
NCT05518383 -
B-cell Mature Non-Hodgkin's Lymphoma Treatment Protocol in Children and Adolescents 2021
|
Phase 4 | |
| Terminated |
NCT01028716 -
Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies
|
Phase 2 |